ArticleTherapeutic advances in musculoskeletal disease2011
Diagnosis and treatment of the idiopathic inflammatory myopathies.
Article in Therapeutic advances in musculoskeletal disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Case Report of an Atypical Presentation of Inclusion Body Myositis Masquerading as Polymyalgia Rheumatica.Current rheumatology reviews · 2026Article
- Immune Myositis Complicating Follicular Lymphoma: Case Report.Reports (MDPI) · 2025Article
- Long-term oral glucocorticoid use is associated with complications, healthcare resource utilization, and costs among patients with dermatomyositis or polymyositis.Clinical rheumatology · 2025Article
- Molecular imaging and immune cell adhesion via vascular adhesion protein-1 in idiopathic inflammatory myopathy: a case report.EULAR rheumatology open · 2025Article
- MGB-Unet: An Improved Multiscale Unet with Bottleneck Transformer for Myositis Segmentation from Ultrasound Images.Journal of imaging informatics in medicine · 2025Article
- Article
- Nontuberculous mycobacterial myositis in dermatomyositis with long-term use of immunosuppressant: a case report.Skeletal radiology · 2024Article
- Incidence and prevalence of idiopathic inflammatory myopathies in Thailand from the Ministry of Public Health data analysis.Scientific reports · 2024Article
- Clinical Features and Outcomes of Patients with Idiopathic Inflammatory Myositis-Associated Interstitial Lung Disease in Rural Appalachia: A Cross-Sectional Study.Journal of clinical medicine · 2024Article
- The use of metaphors by service users with diverse long-term conditions: a secondary qualitative data analysis.Qualitative research in medicine & healthcare · 2023Article
- Review
- Article
- Retinal changes in patients with idiopathic inflammatory myopathies: A case-control study in the MyoCite cohort.Frontiers in medicine · 2022Article
- Polymyositis and dermatomyositis - challenges in diagnosis and management.Journal of translational autoimmunity · 2019Article
- Effect of butylphthalide intervention on experimental autoimmune myositis in guinea pigs.Experimental and therapeutic medicine · 2018Article
- Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.Current rheumatology reports · 2015Review
- Inclusion body myositis: a case of bilateral extremity weakness.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The idiopathic inflammatory myopathies (IIMs) are rare disorders with the unifying feature of proximal muscle weakness. These diseases include polymyositis(PM), dermatomyositis (DM) and inclusion body myositis (IBM) as the most common. The diagnosis is based on the finding of weakness on exam, elevated muscles enzymes, characteristic histopathology of muscle biopsies, electromyography abnormalities and rash in DM. Myositis-specific antibodies have been helpful in defining subsets of patients with different responses to treatment and prognosis. The cornerstone of therapy is corticosteroids with the addition of other immunosuppressives in severe or refractory disease or patients with intolerable side effects. IBM is particularly difficult to treat but is more slowly progressive as compared with PM or DM. There is still a great need to find more effective and less-toxic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.